← Leaderboards
Samuel Wilkinson
Yale University
$5,162,805
Attributed
$6,565,070
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,565,070 · 4
By mechanism
R01$5,407,476 · 2
R21$1,157,594 · 2
Top collaborators
- Taeho Gregory Rhee5 shared
- Rajiv Radhakrishnan2 shared
Most similar at Yale University
Same institution · by research overlap
- Jeffrey M Testani$18,552,037
- Sarwat I Chaudhry$22,426,406
- Marjorie Funk$6,169,567
- Lisa F Berkman$24,689,567
- Leora Horwitz$172,853,120
Others in their field
Other Emerging Leaders on “Future”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$128,483,161
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
FutureMortalityUnited StatesSuicidal RiskSuicide RateFeeling SuicidalSuicideHospitalizationHigh RiskPublic HealthProgramsFollow-UpPersonsMental DepressionEffectivenessPharmaceutical PreparationsSuicidal MorbidityMajor Depressive DisorderAdmission ActivityMeta-AnalysisGeneral PopulationOpen LabelDisease RemissionPattern
Grant awards (13)
Examining Intensive Outpatient Programs as a Potential Mechanism to Reduce Suicide Risk During the Post-Hospitalization Period Among Medicaid Recipients$692,494
R01 · FY2025 · MH · contact PI
Examining Intensive Outpatient Programs as a Potential Mechanism to Reduce Suicide Risk During the Post-Hospitalization Period Among Medicaid Recipients$714,786
R01 · FY2024 · MH · contact PI
Impact of cannabis legalization on prescription drug use and health outcomes in Connecticut$208,330
R21 · FY2024 · DA
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation$966,043
R01 · FY2023 · MH · contact PI
Examining Intensive Outpatient Programs as a Potential Mechanism to Reduce Suicide Risk During the Post-Hospitalization Period Among Medicaid Recipients$763,331
R01 · FY2023 · MH · contact PI
Impact of cannabis legalization on prescription drug use and health outcomes in Connecticut$267,110
R21 · FY2023 · DA
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation$968,989
R01 · FY2022 · MH · contact PI
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation$124,154
R01 · FY2022 · MH · contact PI
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation$575,520
R01 · FY2021 · MH · contact PI
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation$602,159
R01 · FY2020 · MH · contact PI
Association of electroconvulsive therapy with health outcomes in older adults with co-occurring depression and dementia$221,529
R21 · FY2020 · MH · contact PI
Effects of electroconvulsive therapy on suicide in geriatrics patients with major depressive disorder: a nationwide cohort study using propensity score matching and instrumental variable analysis$125,625
R21 · FY2020 · MH · contact PI
Effects of electroconvulsive therapy on suicide in geriatrics patients with major depressive disorder: a nationwide cohort study using propensity score matching and instrumental variable analysis$335,000
R21 · FY2019 · MH · contact PI